Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-MECH: Atrasentan in IgA Nephropathy
NCT07820995Phase 4Not yet recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 4 trial of atrasentan in IgA nephropathy (IgAN), sponsored by University of Illinois Chicago. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07820995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820995.